latest news releases from the newsroom
AdZone Research, Inc.
AdZone Research Expands Its Advisory Committee, Adding Global Terrorism Expert Dr. Jonathan R. White
RIVERHEAD, N.Y., Sept. 16, 2002 (PRIMEZONE) -- AdZone Research, Inc. (OTCBB:ADZR), a pioneering Internet surveillance technology solutions provider, today announced that Dr. Jonathan R. White, widely regarded as one of the world's foremost authorities on terrorism, has joined its advisory committee helping to guide the company's Global Defense Group's efforts.
Endovasc Ltd., Inc.
Endovasc Ltd., Inc.: Biotech Company with the Only Angiogenesis Drug Approved for FDA Phase III Human Clinical Trials Creates a New Subsidiary
MONTGOMERY, Texas, Sept. 17, 2002 (PRIMEZONE) -- Endovasc Ltd., Inc. (OTCBB:ENVC) announced today that in accordance with its new business model, the company has established a new subsidiary, Angiogenix Development Corporation, for its potential blockbuster nicotinic acetylcholine receptor agonist drug -- ANGIOGENIX(tm). Endovasc is well ahead of all other biotech firms in bringing an angiogenesis drug to the market. The company's larger competitors, Genentech (NYSE:DNA) and Genzyme (Nasdaq:GENZ) are still in Phase II trials with their angiogenesis treatments and are experiencing various challenges, whereas Endovasc's treatment has already been approved for FDA Phase III human clinical trials.